Tweet This

More health insurance companies are deciding to pay for a drug based on whether it's effective and provides the patient a good outcome as value-based care inches toward the pharmaceutical industry, insurers and a new analysis indicate.

It’s a trend that’s not going away as major insurers
Aetna,
Anthem,
Cigna,
UnitedHealth Group and Blue Cross and Blue Shield plans work to reduce health spending by getting patients the right care, in the right place and at the right time. The value-based model means doctors and hospitals and increasingly drug makers are paid based on the quality of the care they provide rather than being reimbursed for the volume of care they deliver no matter how it turns out for the patient.

“We have created seven such arrangements in the past two years that base reimbursement on the efficacy of the drug, not just the consumption or volume of the drug,” Cigna CEO David Cordani told analysts earlier this month on the company’s first-quarter earnings call.